Polio (poliomyelitis) is a highly infectious viral disease caused by poliovirus that can invade the nervous system and cause irreversible paralysis.
Measles cases are reappearing across the United States, challenging health systems unprepared for a disease declared eliminated in 2000. Clinical leaders must ensure rapid identification, isolation protocols, and vaccination strategies to prevent outbreaks.
WHO has granted Phase II pre-qualification for Biological E Limited's novel Oral Polio Vaccine type 2, enabling full end-to-end manufacturing at a single integrated site in Hyderabad.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07338851 |
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines |
NOT_YET_RECRUITING | |
| NCT06920069 |
Study of Concomitant Administration of the sIPV and DTaP or MMR |
NOT_YET_RECRUITING | PHASE4 |
| NCT06748612 |
Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) |
NOT_YET_RECRUITING | PHASE4 |
| NCT06605755 |
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants |
RECRUITING | NA |
| NCT06460545 |
Phase IV Study of Concomitant Administration of the sIPV and HepA |
NOT_YET_RECRUITING | PHASE4 |
| NCT06218368 |
A Tool Kit to Improve Vaccine Confidence in the Philippines |
ACTIVE_NOT_RECRUITING | NA |
| NCT06162104 |
Evaluation of Fatigue Severity, Mood, and Quality of Life in Post-Polio Syndrome |
COMPLETED | |
| NCT06114810 |
Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV |
UNKNOWN | PHASE4 |
| NCT06058429 |
Immunogenicity of After Primary Immunization and Booster Immunization of sIPV |
ACTIVE_NOT_RECRUITING | |
| NCT05850364 |
A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine |
COMPLETED | PHASE3 |
